Cardio3 Biosciences to acquire OnCyte portfolio from Celdara Medical.

Cardio3 Biosciences, a developmer of cell therapies, agreed to acquire OnCyte division from Celdara Medical, a company that transforms academic innovations into medicines. Financial terms are not disclosed. “We are extremely proud of everything that the OnCyte team has accomplished to date. The product candidates they have developed could have a tremendous impact on the field of oncology, and we believe that Cardio3 BioSciences is the optimal partner to lead the further advancement of this groundbreaking technology. Cardio3 BioSciences possesses the right scientific, manufacturing, and clinical expertise to continue developing these therapies and to realize their full potential," Jake Reder, Celdara Medical Co-founder and CEO.